APA

Niemoeller E., Souhami E., Wu Y. & Jensen K. H. (2018). iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L. : Diabetes therapy : research, treatment and education of diabetes and related disorders.

Chicago

Niemoeller Elisabeth, Souhami Elisabeth, Wu Yujun and Jensen Klaus H. 2018. iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L. : Diabetes therapy : research, treatment and education of diabetes and related disorders.

Harvard

Niemoeller E., Souhami E., Wu Y. and Jensen K. H. (2018). iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L. : Diabetes therapy : research, treatment and education of diabetes and related disorders.

MLA

Niemoeller Elisabeth, Souhami Elisabeth, Wu Yujun and Jensen Klaus H. iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L. : Diabetes therapy : research, treatment and education of diabetes and related disorders. 2018.